### REVIEW



# Local administration of gentamicin collagen sponge in surgical excision of sacrococcygeal pilonidal sinus disease: a systematic review and meta-analysis of the literature

A. L. Nguyen<sup>1</sup> · A. A. Pronk<sup>1</sup> · E. J. B. Furnée<sup>1</sup> · A. Pronk<sup>1</sup> · P. H. P. Davids<sup>1</sup> · N. Smakman<sup>1</sup>

Received: 7 March 2015/Accepted: 18 August 2015/Published online: 6 November 2015 © Springer-Verlag Italia Srl 2015

**Abstract** Surgical site infections occur in up to 24 % of patients after surgical excision of sacrococcygeal pilonidal sinus disease with primary wound closure. Local administration of antibiotics by a gentamicin collagen sponge could reduce this infection rate. The objective of this systematic review and meta-analysis was to evaluate the effect of a gentamicin collagen sponge on outcome after surgical excision in patients with sacrococcygeal pilonidal sinus disease. A structured literature search was performed in the PubMed, Embase, The Cochrane Library, and Scopus databases. Studies comparing surgical excision of sacrococcygeal pilonidal sinus disease with versus without a gentamicin collagen sponge were included. Outcome measures were surgical site infection, wound healing, and recurrence. The search strategy yielded six studies with a total of 669 patients. Three randomized controlled trials, comparing excision of pilonidal sinus disease and primary wound closure with versus without gentamicin collagen sponge, were eligible for inclusion in the meta-analysis (319 patients), demonstrating a trend towards reduced surgical site infections after administration of gentamicin collagen sponge [absolute risk reduction 20 %. 95 %-confidence interval (CI) 1–41 %, p = 0.06]. The wound healing (absolute risk reduction 22 %, 95 % CI 32–77 %, p = 0.42) and recurrence rate (absolute risk reduction 8 %, 95 % CI 7–22 %, p = 0.30) were not significantly different between both groups. Administration of a gentamicin collagen sponge after surgical excision of sacrococcygeal pilonidal sinus disease showed no

N. Smakman nsmakman@diakhuis.nl significant influence on wound healing and recurrence rate, but a trend towards a reduced incidence of surgical site infections. Therefore, additional larger well-designed randomized controlled trials are required.

**Keywords** Sacrococcygeal pilonidal sinus disease · Gentamicin sponge · Surgical site infection · Wound healing · Recurrence

### Introduction

Sacrococcygeal pilonidal sinus disease (SPSD) is an acquired disorder of the skin and subcutaneous tissue. It is most common among young adults, affecting men twice more often than women [1-3]. Patients present with recurrent or persistent discharge, discomfort and/or pain in the natal cleft. The treatment of SPSD involves eradication of the sinus tract by surgical excision, deroofing or phenol application. Radical excision of the sinus, however, is the most commonly applied treatment option. Healing of the overlying skin can be achieved by primary wound closure, in-midline, off-midline, i.e. Karydakis flap reconstruction, or rarely, with Limberg flap reconstruction. In recent decades, off-midline closure has become the preferred method due to a lower recurrence rate [4, 5] and the Karydakis Flap reconstruction is advised for treatment of uncomplicated SPSD [6]. The disadvantage of primary closure, however, is the high rate of surgical site infection, occurring in up to 24 % of patients [1, 3, 4, 7]. Another commonly applied method after radical excision is secondary healing of the wound by open granulation; however, this results in a longer wound healing time [4, 5].

Administration of systemic antibiotics after primary wound closure may be an option to reduce the incidence of

<sup>&</sup>lt;sup>1</sup> Department of Surgery, Diakonessenhuis, Bosboomstraat 1, P.O. Box 80250, 3508 TG Utrecht, The Netherlands

surgical site infections. However, several randomized controlled trials (RCTs) have not shown any significant benefit [8–11]. Therefore, local application of a gentamicin collagen sponge in the wound cavity after excision of the SPSD has been introduced to reduce the incidence of surgical site infections. Compared to systemic antibiotics, this local administration leads to prolonged and higher local therapeutic concentrations [12, 13]. Several RCTs have been performed comparing primary wound closure with the administration of a gentamicin collagen sponge after surgical excision of SPSD versus either primary wound closure [14-16] or secondary wound healing [17, 18], both without a gentamicin collagen sponge. The outcome regarding surgical site infection, wound healing, and recurrence rate is quite different in these studies. Therefore, to date, a consensus on the optimal treatment for SPSD with regard to the local administration of antibiotics does not exist.

The objective of this systematic review and meta-analysis was to analyze whether the local intraoperative administration of a gentamicin collagen sponge after excision of SPDS benefits the outcome with regard to surgical site infection, wound healing, and recurrence rate.

### Methods

A systematic review and meta-analysis was conducted according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) [19].

### Search strategy

A search of the literature was conducted in the databases of PubMed, Embase, and the Cochrane Library on October 30, 2014. Different synonyms for "SPSD", "gentamicin", "local antibiotics", "surgical site infection", "wound healing," and "recurrence" were used as search terms (Table 1). For the search in PubMed, additional MeSH terms were used. No search limitations were applied. Additionally, cited references of the included articles were screened using the Scopus database. Finally, reference lists of the included articles were manually searched in order to identify potentially eligible studies.

### Study selection

Studies were screened on title, abstract, and full texts for identifying potentially relevant studies according to predefined inclusion criteria. Studies were included if the patients had SPSD. The intervention consisted of application of a gentamicin collagen sponge versus no gentamicin collagen sponge after surgical excision of the SPSD. The primary outcomes were surgical site infection, wound healing, and/or recurrence. All types of study design were included. Studies describing patients with an abscess and treatment options other than surgical excision were excluded from further analysis.

### Quality assessment

The included studies were methodologically assessed, according to the items described in the Cochrane handbook for systematic reviews of interventions, version 5.1.0 [20]. Additionally, the level of evidence was assessed according to the Centre for Evidence Based Medicine at the University of Oxford [21].

### **Data acquisition**

Data of the included studies were acquired by using a standard data extraction form, collecting information on the year of publication, study design, sample size, wound closure technique, size and number of gentamicin collagen sponges, duration of follow-up, surgical site infection rate, wound healing rate, time to wound healing, and recurrence rate.

### Statistical analysis


Data were analyzed by using RevMan 5.2 software (Review Manager Version 5.0: The Nordic Cochrane Centre, Copenhagen; The Cochrane Collaboration, 2012). Outcome parameters were summarized per individual study using absolute risks (AR), absolute risk reduction (ARR), and the number needed to treat (NNT) with corresponding 95 % confidence intervals (95 % CI). Statistical heterogeneity of the pooled data was assessed by using the Chi-square test and  $I^2$  statistic. Heterogeneity was considered statistically significant with p < 0.1 and  $I^2 > 75$  %. Forest plots were made for the absolute risk differences (RD) using a random effects model, since significant statistical heterogeneity was present.

### **Results**

The original search yielded 40 articles. After removal of duplicates, 22 articles remained which were screened on title and abstract according to predefined inclusion criteria. Subsequently, ten articles remained and were screened on full text. Eventually, five RCTs [14–18] and one retrospective case–control study [22] were eligible for inclusion (Fig. 1).

Table 1   Search	terms
Patient population	Pilonidal OR "Pilonidal Sinus" [Mesh] OR 'coccygeal sinus' OR 'sacrococcygeal sinus' OR (jeep AND disease) OR (hair- containing AND abscess) OR (hair-containing AND sinus) OR (tailbone AND cyst) OR (tailbone AND abscess)
Intervention	Gentamicin OR gentacycin OR gentacycol OR genticin OR garamycin OR gentavet OR G-myticin OR 'G Myticin' OR "Gentamicins" [Mesh] OR (collagen AND sponge) OR (local AND antibiotic) OR (local AND antibiotics) OR (local AND anti-bacterial) OR (local AND anti bacterial) OR (local AND antibacterial) OR (local AND antibicterial) OR (local AND bacteriocidal) OR (local AND bacteriocides)
Outcome parameters	'Surgical wound infection' OR 'surgical wound infections' OR "Surgical wound infection" [Mesh] OR 'postoperative wound infection' OR 'postoperative wound infections' (wound AND healing) OR 'surgical wound dehiscence' OR "Surgical Wound Dehiscence" [Mesh] OR recurrence OR recurrences OR "Recurrence" [Mesh] OR relapse OR recrudescence OR recrudescences

Fig. 1 Flowchart of search strategy and study selection



The methodological quality assessment of the five included RCTs is shown in Table 2. Andersson et al. [14] had no negative score on any of the assessed items. The method of randomization was not reported in two studies [16, 17]. Studies performed by Vogel et al. [15] and Rao et al. [18] had a loss to follow-up of more than 10 %. In four trials, blinding of patients, surgeons, and assessors for the intervention and whether analysis was performed according to the intention to treat principle was not reported [15–18]. Doll et al. [22] executed a retrospective case–control study (excision of SPSD with or without gentamicin collagen sponge). The study groups and interventions were adequately described, and outcomes were adequately assessed according to predefined criteria.

The level of evidence according to the Oxford Centre for Evidence Based Medicine for the five RCTs [14–18] was 1b and for the individual cohort study [22] was 2b.

# Primary closure with versus without gentamicin collagen sponge

Three RCTs [14–16] and one retrospective case control study [22] were conducted comparing surgical excision followed by primary closure with or without a gentamicin collagen sponge.

Andersson et al. [14] executed a double-blinded multicenter RCT in Sweden comparing primary closure with (77 patients) versus without a gentamicin collagen sponge (82 patients) after surgical excision of SPSD (Table 3). This study showed no significant differences in terms of surgical site infection rates at 2 weeks after surgery (Table 4). The wound healing and recurrence rate at one-year follow-up were also not significantly different between the groups (Tables 5 and 6, respectively).

Vogel et al. [15] performed a RCT in Germany, with 40 patients in each group, comparing application of a gentamicin collagen sponge versus no gentamicin collagen sponge after surgical excision (Table 3). One to four gentamicin collagen sponges were administrated depending on the size of the wound. With regard to surgical site infections, the ARR was 42.5 % (95 % CI 25.0–60.0, p < 0.001) in favor of the gentamicin collagen sponge group with a corresponding number needed to treat (NNT) of 3.0 (95 % CI 1.7–4.0) (Table 4). The absolute risk reduction (ARR) of the rate of non-healed wounds was 50.0 % (95 % CI 31.8–68.2), p < 0.001) in favor of agentamicin collagen sponge (Table 5). No recurrences occurred at follow-up (Table 6).

Yetim et al. [16] conducted a RCT in Turkey with 80 patients, comparing local administration of a gentamicin

	Random sequence generation (selection bias)	Concealment of allocation (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Analysis conform intention to treat	Cross- over >10 %
Andersson et al. [14]	+	+	+	+	+	+	+	NA
Vogel et al. [15]	++	NR	NR	NR	-	+	NR	NR
Yetim et al. [16]	±	NR	NR	NR	+	+	NR	NR
Holzer et al. [17]	±	NR	NR	NR	+	-	NR	NR
Rao et al. [18]	+	NR	NR	NR	±	-	NR	NR

Table 2 Methodological quality assessment of included randomized trials

Random sequence generation: ++ Randomization by computer system or random table, + Randomization by closed/sealed envelopes,  $\pm$  Randomization method not reported; - No randomization

Concealment of allocation: + Yes; - No

Blinding of participants and personnel: + Yes; - No

Blinding of outcome assessment: + Yes; - No

Incomplete outcome data: + < 10 %;  $\pm 10-15$  %; - >15 %

Selective reporting: + all pre-specified outcomes have been reported, - not all pre-specified outcomes have been reported incompletely

Analysis conform intention to treat: + Yes; - No

Cross-over: + < 10%;  $\pm 10-15\%$ ; - > 15%

NR not reported, NA not applicable

Table 3 Study characteristics	tics						
	Study design	LoE	Closure technique	Study groups	GCS size and number	Outcomes	Follow-up
Andersson et al. [14]	MC RCT	1B	Primary midline closure	GCS $(n = 82)$ versus no GCS (n = 77)	1 GCS	Surgical site infection Delayed wound healing Recurrences	2 weeks 1 year 1 vear
Vogel et al. [15]	SC RCT	1B	Primary midline closure	GCS $(n = 40)versus no GCS(n = 40)$	1-4 GCS	Surgical site infection Delayed wound healing Recurrences	1 year 1 year 1 year
Yetim et al. [16]	SC RCT	1B	Primary midline closure	GCS $(n = 40)$ versus oral antibiotics (n = 40)	Whole $5 \times 5 \times 0.5 \text{ cm}$ GCS	Surgical site infection Time to healing Recurrences	1 year NR 1 year
Doll et al. [22]	Я	2B	Primary midline closure	GCS $(n = 111)$ versus no GCS (n = 76)	NR	Surgical site infection Delayed wound healing Recurrences	15 years 15 years 15 years
Holzer et al. [17]	MC RCT	1B	Primary midline closure versus secondary wound healing	GCS (n = 51)versus no GCS (n = 52)	Whole $5 \times 8 \text{ cm GCS}$	Delayed wound healing Time to healing Recurrences	2 weeks NR 26 week
Rao et al. [18]	SC RCT	1B	Primary midline closure versus secondary wound healing	GCS (n = 30) versus no GCS (n = 30)	Whole 1–2 GCS	Delayed wound healing Time to healing Recurrences	4 weeks NR 5 years
GCS Gentamicin collagen trial	sponge, LoE lev	el of evidenc	e, MC multicenter, N numbe	r of patients, NR not reported, S	C single center, R retrospe	GCS Gentamicin collagen sponge, LoE level of evidence, MC multicenter, N number of patients, NR not reported, SC single center, R retrospective cohort study, RCT randomised controlled trial	sed controlled

<i>Primary closure with versus without gentamicin collagen sponge</i> Andersson et al. [14]18/82 $2077$ $220(14.3-32.1)$ $260(174-36.8)$ $4.0(-9.3-17.3)$ $0.55$ $250(NNTH 10.8 to \infty)$ $2 weeks$ Andersson et al. [14]18/82 $2077$ $220(14.3-32.1)$ $26.0(174-36.8)$ $4.0(-9.3-17.3)$ $0.55$ $250(NNTH 10.8 to \infty)$ $2 weeks$ Vogel et al. [15] $3/40$ $20/40$ $7.5(19-20.6)$ $500(35.2-64.8)$ $4.2.5(25.0-60.0)$ $-0.001$ $3.0(17-4.0)$ $1 year$ Yeim et al. [16] $2/40$ $8/40$ $50(0.5-17.4)$ $200(10.2-55.0)$ $15.0(0.9-29.0)$ $0.04$ $7.0(34-113.2)$ $1 year$ Doll et al. [22] $20/111$ $2476$ $18.0(11.9-26.3)$ $31.6(22.2-42.7)$ $13.6(0.9-26.2)$ $0.03$ $8.0(3.8-111.3)$ $1 year$ Doll et al. [21] $20/111$ $2476$ $18.0(11.9-26.3)$ $31.6(22.2-42.7)$ $13.6(0.9-26.2)$ $0.03$ $8.0(3.8-111.3)$ $1 year$ Primary closure with gentamicin collagen sponge versus secondary wound healing without gentamicin collagen sponge $N R$ $N R$ $N R$ $N R$ $N R$ $N R$ Holzer et al. [17] $251$ $N R$ A bolzer et al. [18] $N R$ A bolzer et al. [19] $N R$ A bolzer et al. [19] $N R$ $N R$ $N R$	gentamicin collagen spon, 20/77 20/40 8/40 24/76 24/76 24/76 agen sponge versus secon NR NR NR NR agen sponge versus secon agen sponge versus secon	<i>ge</i> 22.0 (14.3–32.1) 7.5 (1.9–20.6) 5.0 (0.5–17.4) 18.0 (11.9–26.3) <i>adary wound healing v</i> 3.9 (0.3–14.0) NR NR interval, <i>GCS</i> gentam d to benefit, <i>NNTH</i> nu	26.0 (17.4–36.8) 50.0 (35.2–64.8) 20.0 (10.2–35.0) 31.6 (22.2–42.7) without gentamicin col NR NR NR icin collagen sponge, miber needed to harm	4.0 (-9.3-17.3) 42.5 (25.0-60.0) 15.0 (0.9-29.0) 13.6 (0.9-26.2) 13.6 sponge NR NR NR number of patients <i>n</i> number of patients	0.55 <0.001 0.04 0.03 NR NR NR NR	25.0 (NNTH 10.8 to ∞ to NNTB 5.8) 3.0 (1.7-4.0) 7.0 (3.4-113.2) 8.0 (3.8-111.3) 8.0 (3.8-111.3) NR NR NR NR	2 weeks 1 year 1 year 15 years NA NA NA ents, <i>NA</i> not
Andersson et al. [14] 18/82 Vogel et al. [15] 3/40 Yetim et al. [16] 2/40 Doll et al. [22] 20/111 <i>Primary closure with gentamicin collag</i> Holzer et al. [17] 2/51 Rao et al. [18] NR AR Absolute risk, ARR absolute risk re applicable, NNT number needed to trea	20/77 20/40 8/40 24/76 24/76 agen sponge versus secon NR NR NR NR at, NNTB number needec	22.0 (14.3–32.1) 7.5 (1.9–20.6) 5.0 (0.5–17.4) 18.0 (11.9–26.3) adary wound healing v 3.9 (0.3–14.0) NR NR interval, <i>GCS</i> gentam d to benefit, <i>NNTH</i> nu	26.0 (17.4-36.8) 50.0 (35.2-64.8) 20.0 (10.2-35.0) 31.6 (22.2-42.7) without gentamicin col NR NR NR itcin collagen sponge, mhor needed to harm	4.0 (-9.3-17.3) 42.5 (25.0-60.0) 15.0 (0.9-29.0) 13.6 (0.9-26.2) 13.6 sponge NR NR NR number of patients <i>n</i> number of patients	0.55 <0.001 0.04 0.03 0.03 NR NR NR NR	25.0 (NNTH 10.8 to ∞ to NNTB 5.8) 3.0 (1.7–4.0) 7.0 (3.4–113.2) 8.0 (3.8–111.3) NR NR NR NR NR NR	2 weeks 1 year 15 years NA NA NA ents, <i>NA</i> not
Vogel et al. [15] 3/40 Yetim et al. [16] 2/40 Doll et al. [22] 20/111 <i>Primary closure with gentamicin collag</i> Holzer et al. [17] 2/51 Rao et al. [18] NR AR Absolute risk, ARR absolute risk re applicable, NNT number needed to trea	20/40 8/40 24/76 24/76 agen sponge versus secon NR NR NR NR at, NNTB number needec	7.5 (1.9–20.6) 5.0 (0.5–17.4) 18.0 (11.9–26.3) <i>adary wound healing v</i> 3.9 (0.3–14.0) NR interval, GCS gentarr interval, GCS gentarr d to benefit, <i>NNTH</i> nu	50.0 (35.2-64.8) 20.0 (10.2-35.0) 31.6 (22.2-42.7) without gentamicin col. NR NR NR icin collagen sponge, miber needed to harm	42.5 (25.0–60.0) 15.0 (0.9–29.0) 13.6 (0.9–26.2) lagen sponge NR NR number of patients <i>n</i> number of patients	<0.001 0.04 0.03 0.03 NR NR NR with positive outco	3.0 (1.7–4.0) 7.0 (3.4–113.2) 8.0 (3.8–111.3) NR NR NR ine, N total number of pati	1 year 1 year 15 years NA NA NA ents, <i>NA</i> not
Yetim et al. [16] 2/40 Doll et al. [22] 20/111 <i>Primary closure with gentamicin colla</i> Holzer et al. [17] 2/51 Rao et al. [18] NR <u>AR</u> Absolute risk, ARR absolute risk re applicable, <i>NNT</i> number needed to trea	8/40 24/76 24/76 agen sponge versus secon NR NR reduction, CI confidence cat, NNTB number needec	5.0 (0.5-17.4) 18.0 (11.9-26.3) <i>adary wound healing</i> y 3.9 (0.3-14.0) NR interval, <i>GCS</i> gentam interval, <i>GCS</i> gentam	20.0 (10.2-35.0) 31.6 (22.2-42.7) without gentamicin col. NR NR nicin collagen sponge, miber needed to harm	15.0 (0.9–29.0) 13.6 (0.9–26.2) lagen sponge NR NR n number of patients <i>NR</i> not reported	0.04 0.03 NR NR with positive outco	7.0 (3.4–113.2) 8.0 (3.8–111.3) NR NR ine, <i>N</i> total number of pati	1 year 15 years NA NA ents, <i>NA</i> not
Doll et al. [22] 20/111 <i>Primary closure with gentamicin collag</i> Holzer et al. [17] 2/51 Rao et al. [18] NR <u>AR Absolute risk, ARR absolute risk re</u> applicable, <i>NNT</i> number needed to trea	24/76 agen sponge versus secon NR NR reduction, CI confidence cat, NNTB number needec	18.0 (11.9–26.3) adary wound healing v 3.9 (0.3–14.0) NR interval, GCS gentan d to benefit, NNTH nu	31.6 (22.2-42.7) without gentamicin col. NR NR nr nr nicin collagen sponge,	13.6 (0.9–26.2) lagen sponge NR NR n number of patients NR not reported	0.03 NR NR with positive outco	8.0 (3.8–111.3) NR NR me, <i>N</i> total number of pati	15 years NA NA ents, <i>NA</i> not
Primary closure with gentamicin collag Holzer et al. [17] 2/51 Rao et al. [18] NR <u>AR Absolute risk, ARR absolute risk re</u> applicable, <i>NNT</i> number needed to trea	agen sponge versus secon NR NR reduction, CI confidence sat, NNTB number needec	<i>idary wound healing v</i> 3.9 (0.3–14.0) NR interval, GCS gentarr d to benefit, <i>NNTH</i> nu	vithout gentamicin coll NR NR nicin collagen sponge, umber needed to harm	lagen sponge NR NR n number of patients NR not reported	NR NR with positive outed	NR NR me, <i>N</i> total number of pati	NA NA ents, <i>NA</i> not
Holzer et al. [17] 2/51 Rao et al. [18] NR AR Absolute risk, ARR absolute risk re applicable, NNT number needed to trea	NR NR reduction, <i>CI</i> confidence sat, <i>NNTB</i> number needec	3.9 (0.3–14.0) NR interval, <i>GCS</i> gentard d to benefit, <i>NNTH</i> nu	NR NR nicin collagen sponge,	NR NR <i>n</i> number of patients <i>NR</i> not reported	NR NR with positive outco	NR NR ine, <i>N</i> total number of pati	NA NA ents, <i>NA</i> not
Rao et al. [18] NR AR Absolute risk, ARR absolute risk re applicable, NNT number needed to trea	NR reduction, <i>CI</i> confidence cat, <i>NNTB</i> number needec	NR interval, GCS gentan d to benefit, NNTH nu	NR nicin collagen sponge, mher needed to harm	NR <i>n</i> number of patients <i>NR</i> not reported	NR with positive outco	NR ome, N total number of pati	NA ents, NA not
AR Absolute risk, ARR absolute risk re applicable, NNT number needed to trea	reduction, CI confidence sat, NNTB number needec	interval, GCS gentard d to benefit, NNTH nu	aicin collagen sponge, umber needed to harm	<i>n</i> number of patients <i>NR</i> not reported	with positive outco	me, N total number of pati	ents, NA not
Table 5 Rates of non-healed wounds							
Treatment (GCS) <i>n/</i> N	Control N (no GCS) n/N	AR GCS (%) (95 % CI)	AR no GCS (%) (95 % CI)	ARR in (%) (95 % CI)	<i>p</i> value for ARR	· NNT (95 % CI)	Follow-up
Primary closure with versus without gentamicin collagen sponge Andersson et al. [14] 12/82 8/77	gentamicin collagen spon. 8/17	<i>ge</i> 14.6 (8.4–24.0)	10.4 (5.1–19.4)	-4.2 (-6.0-14.5)	0.42	NNTH = 24 (NNTH 6.9 to $\infty$ to	1 year

🖄 Springer

96

Tech Coloproctol (2016) 20:91-100

15 years

1 year NA

2.0 (1.5-3.1)

<0.001

50.0 (31.8-68.2)

62.5 (47.0–75.8)

12.5 (5.0-26.6)

25/40

5/40

Vogel et al. [15] Yetim et al. [16] Doll et al. [22]

NA

NR

0 NR

0 NR

NR NA

NR NA 2 weeks 4 weeks

NR 2.0 (1.1–1.7)

< 0.001

76.7 (60.4-92.9)

86.7 (69.7-95.3)

NR

ßR

27.5 (17.0-41.0)

10.0 (2.7-26.4)

26/30

ЯR

14/51

Holzer et al. [17]

Rao et al. [18]

3/30

Primary closure with gentamicin collagen sponge versus secondary wound healing without gentamicin collagen sponge

NR 0/76

0/111

ЯR

ЯR

AR Absolute risk, ARR absolute risk reduction, CI confidence interval, GCS gentamicin collagen sponge, n number of patients with positive outcome, N total number of patients, NA not applicable, NNT number needed to treat, NNTB number needed to benefit, NNTH number needed to harm, NR not reported

	I reatment (GCS) n/N	(no GCS) n/N (%) (95 % CI)	AK UCS (%) (95 % CI)	(95 % CI)	(95 % CI)	ARR		da nono r
Primary closure with versus without gentamicin collagen sponge	versus without g	entamicin collagen.	estimation					
Andersson et al. [14] 9/82	9/82	<i>TT1</i>	11.0 (5.7–19.8)	11.7 (6.1–21.0)	0.7 (-9.2-10.6)	0.89	141.0 (NNTH 10.9 to $\infty$ to NNTB 9.5)	1 year
Vogel et al. [15]	0/NR	0/NR	0	0	NA	NA	NA	1 year
Yetim et al. [16]	0/40	6/40	0 (0-10.4)	15.0 (6.7–29.5)	15.0 (4.0-26.1)	0.01	7.0 (3.8–25.4)	1 year
Doll et al. [22]	34/111	20/76	30.6 (22.8–39.8)	26.3 (17.7–37.2)	-4.3 (-8.8-17.4)	0.52	NNTH = 24.0 (NNTH 5.7 to $\infty$ to NNTB 11.4)	15 years
Primary closure with gentamicin collagen sponge versus secondary wound healing without gentamicin collagen sponge	gentamicin colla	s snss aboude versus	secondary wound her	aling without gentam	vicin collagen sponge			
Holzer et al. [17]	1/51	0/52	2.0 (0-11.3)	0 (0–8.2)	-2.0 (-1.8-5.8)	0.31	NNTH = 51.0 (NNTH 17.3 to $\infty$ to NNTB 54.2)	26 weeks
Rao et al. [18]	2/25	2/24	8.0 (1.1–26.1)	8.3 (1.2–27.0)	0.3 (-15.0-15.7)	0.97	300.0 (NNTH 6.7 to $\infty$ to NNTB 6.4)	5 years

**Table 6** Recurrence rates

Tech Coloproctol (2016) 20:91-100

collagen sponge to postoperative oral antibiotic therapy for 7 days after surgical excision with primary midline closure (Table 3). For the outcome surgical site infections, a significant ARR of 15.0 % (95 % CI 0.9–29.0, p = 0.04) was achieved after application of a gentamicin collagen sponge (Table 4). The mean time to wound healing was reported to be shorter after application of a gentamicin collagen sponge (8.9 vs. 15.1 days, p = 0.001) [16]. Additionally, a significant ARR of 15.0 % (95 % CI 4.0–26.1, p = 0.01) in favor of the gentamicin collagen sponge group was demonstrated with regard to recurrence at one-year follow-up (Table 6).


Doll et al. [22] retrospectively examined a population of 187 men with SPSD who underwent excision with primary midline closure with or without a gentamicin collagen sponge (Table 3). Application of a gentamicin collagen sponge yielded a significant ARR of 13.6 % (95 % CI 0.9–26.2, p = 0.03) with regard to surgical site infections (Table 4). All wounds were healed after 12 days. No statistically significant difference in the recurrence rate existed between the groups (Table 6).

# Primary closure with gentamicin collagen sponge versus secondary wound healing without gentamicin collagen sponge


Holzer et al. [17] executed a multicenter RCT in Austria that included 103 patients comparing primary closure with a gentamicin collagen sponge versus secondary wound healing without a gentamicin collagen sponge after surgical excision of SPSD (Table 3). In the gentamicin collagen sponge group, 27.5 % (95 % CI 17.0-41.0 %) of the wounds were not healed at 2-week follow-up. The median time to healing in the primary closure with gentamicin collagen sponge group was 17 days (range 7-39 days) versus 68 days (range 10-161 days) in the secondary wound healing group (p < 0.001) [17]. Two patients in the gentamicin collagen sponge group developed a surgical site infection in the first 2 weeks after surgery, which required conversion to open treatment (Table 4). The surgical site infection and wound healing rates for the secondary wound healing group were not reported. After a follow-up period of 26 weeks, one recurrence was seen in the primary closure group versus none in the open treatment group (Table 6).

Rao et al. [18] performed a single-center RCT in Northern Ireland that enrolled 60 patients who underwent surgical excision of SPSD. In the primary closure group (30 patients), one or two gentamicin collagen sponges were implanted in the wound depending on the size of the wound. The surgical site infection rate was not reported. The rate of non-healed wounds at 4-week follow-up was significantly higher in the group of patients, who

# a Surgical site infection



## **b** Delayed wound healing



 Total (95% CI)
 122
 117
 100.0%
 -0.08 [-0.22, 0.07]

 Total events
 9
 15

 Heterogeneity: Tau<sup>2</sup> = 0.01; Chi<sup>2</sup> = 3.45, df = 1 (P = 0.06); l<sup>2</sup> = 71%
 -1
 -0.5
 0
 0.5
 1

 Test for overall effect: Z = 1.04 (P = 0.30)
 Favours GCS
 Favours no GCS
 Favours no GCS
 -1
 -0.5
 0
 -5
 1

CI Confidence interval; GCS Gentamicin collagen sponge

Fig. 2 Forest plots for surgical site infection (a), delayed wound healing (b), and recurrence rate (c)

underwent surgical excision followed by secondary wound healing without a gentamicin collagen sponge (Table 5). Furthermore, the median wound healing time (interquartile range) was also significantly shorter in the gentamicin collagen sponge group [10 (10–26) days vs. 50 (40–90) days; p < 0.001] [18]. At 5-year follow-up, there was no significant difference in terms of recurrence (Table 6).

# Pooling of data

The study data from three RCTs [14–16] comparing surgical excision followed by primary closure with versus without a gentamicin collagen sponge were pooled. The risk difference (RD) for surgical site infections was 20 % (95 % CI, range 1–41 %) in favor of the treatment with the gentamicin collagen sponge, although this was not statistically significant (p = 0.06) (Fig. 2A). Pooled data of two RCTs [14, 15] reported no significant difference in rate of non-healed wounds at one-year follow-up after administration of local antibiotics (RD 22 %, 95 % CI, range 32–77 %, p = 0.42) (Fig. 2b). Additionally, heterogeneity was significantly present for both outcome parameters. There was no significant difference regarding recurrence rate between both treatments at one-year follow-up (Fig. 2c).

### Discussion

This systematic review summarizes the available literature with regard to the effect of intraoperative local administration of a gentamicin collagen sponge after surgical excision of SPSD. Meta-analysis of three RCTs that investigated surgical excision of SPSD followed by primary closure with versus without a gentamicin collagen sponge demonstrated a trend towards less surgical site infections with the application of a gentamicin collagen sponge. However, the wound healing and recurrence rate were not significantly influenced [14–16]. Additionally, a retrospective cohort study showed a significant reduction in surgical site infection with the administration of a gentamicin collagen sponge, but there was no statistically significant difference in wound healing and recurrence rates [22].

In this meta-analysis, the results did not reach a statistical significant difference in terms of surgical site infection, probably due to relatively small sized and therefore underpowered RCTs. Heterogeneity of the included studies was present as well. However, the results showed a trend towards a reduction in the rate of surgical site infections (p = 0.06). These results are supported by a systematic review and meta-analysis performed by Chang et al. [23], consisting of fifteen RCTs, which confirmed that gentamicin collagen sponges significantly reduce the incidence of surgical site infections after different types of surgery [odds ratio (OR) = 0.51; 95 % CI 0.33–0.77; p = 0.01]. Although current evidence is not yet overly convincing, the advantage of applying a gentamicin collagen sponge is that the antibiotics remain localized and do not enter the systemic circulation. Moreover, no adverse events due to the application of a gentamicin collagen sponge were reported in the included trials.

The results of this systematic review showed no significant difference with regard to wound healing with the use of gentamicin collagen sponges, therefore this still remains a problem in a substantial proportion of patients. It should be noted that primary midline closure was applied in the included studies, whereas several metaanalyses have shown that off-midline closure should be the treatment of choice considering the lower rate of surgical site infections, faster healing rates and lower recurrence rates associated with this type of closure [4, 5]. Additionally, wound healing could be impeded when the gentamicin collagen sponge is inserted between both edges of the wound, as this may become a barrier to adequate wound healing. Some included studies reported details regarding the size [16, 17] and number [14, 15, 18] of inserted sponges in the wound cavity. However, they did not report whether the gentamicin sponge was inserted in the wound as a whole, although some images included in the articles demonstrate that the gentamicin collagen sponge was in situ in the wound after surgical excision as a whole [16–18]. In order to promote wound healing, however, the gentamicin collagen sponge can be cut into small pieces before insertion in the wound cavity. Whether cutting the sponge into small pieces will improve wound healing needs further investigation.

There also were two RCTs [17, 18] included in this systematic review that compared primary wound closure

with a gentamicin collagen sponge versus secondary wound healing (without a gentamicin collagen sponge) after excision of SPSD. The surgical site infection rate was not adequately reported in both studies, and there was no statistically significant difference in recurrence rate between both groups [17, 18]. Both studies reported that in terms of wound healing, primary closure with a gentamicin collagen sponge was superior to secondary wound healing. However, it is commonly known that primary closure accelerates wound healing. Therefore, the additional effect of a gentamicin collagen sponge on wound healing cannot be determined from these studies.

There are a few limitations to this systematic review, which are mainly due to the quality, heterogeneity, and size of the included studies. First, four RCTs [15-18] did not state details about concealment of allocation, and whether blinding for participants, personnel, and patients was performed. Therefore, these studies are at risk for selection bias, performance bias, and detection bias, respectively. Second, two studies [15, 16] reported a remarkable recurrence rate of 0 %, which leads us to question the validity of these studies as this seems, in our opinion, unlikely in this patient population. Third, most RCTs [15-18] did not record whether their studies were appropriately powered. Fourth, it is remarkable that the relatively smaller RCTs showed statistically significant differences with regard to surgical site infections [15, 16], wound healing rate [15], and recurrences [16] by adding a gentamicin collagen sponge to the surgical treatment, whilst the largest RCT [14] does not support these findings. This may be due to publication bias, where statistically significant results may be more likely to be published than non-significant results regardless of the size, design, and methodology of the study. This could lead to overestimation of the effect of the gentamicin collagen sponge. Finally, to the best of our knowledge, the cost-effectiveness of the application of a gentamicin collagen sponge in patients with SPSD has not yet been evaluated. The cost-effectiveness of local application of a gentamicin collagen sponge has been confirmed in the prevention of sternal wound infections following cardiac surgery [24]. However, future research has to be performed to determine whether the application of gentamicin implants in patients with SPSD will also be costeffective.

## Conclusions

This systematic review and meta-analysis has demonstrated that the administration of a gentamicin collagen sponge after surgical excision of SPSD does not accelerate wound healing or reduce the recurrence rate, but there is a trend towards less surgical site infections. Therefore, larger well-designed RCTs are needed in order to demonstrate a more reliable and accurate effect of the application of a gentamicin collagen sponge on the outcome after surgical excision of SPSD.

### **Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent** For this type of study, formal consent is not required.

# References

- 1. Søndenaa K, Andersen E, Nesvik I, Søreide JA (1995) Patient characteristics and symptoms in chronic pilonidal sinus disease. Int J Colorectal Dis 10:39–42
- Akinci OF, Bozer M, Uzunköy A, Düzgün SA, Coşkun A (1999) Incidence and aetiological factors in pilonidal sinus among Turkish soldiers. Eur J Surg 165:339–342
- Khanna A, Rombeau JL (2011) Pilonidal disease. Clin Colon Rectal Surg 24:46–53
- 4. Al-Khamis A, McCallum I, King PM, Bruce J (2010) Healing by primary versus secondary intention after surgical treatment for pilonidal sinus. Cochrane Database Syst Rev (1): CD006213
- Enriquez-Navascues JM, Emparanza JI, Alkorta M, Placer C (2014) Meta-analysis of randomized controlled trials comparing techniques with primary closure for chronic pilonidal sinus. Tech Coloproctol 18:863–872
- Ates M, Dirican A, Sarac M, Aslam A, Colak C (2011) Short and long-term results of the Karydakis flap versus the Limberg flap for treating pilonidal sinus disease: a prospective randomized study. Am J Surg 202:568–573
- 7. Hull TL, Wu J (2002) Pilonidal disease. Surg Clin North Am 82:1169–1185
- Søndenaa K, Diab R, Nesvik I et al (2002) Influence of failure of primary wound healing on subsequent recurrence of pilonidal sinus. Combined prospective study and randomised controlled trial. Eur J Surg 168:614–618
- 9. Kronborg O, Christensen K, Zimmermann-Nielsen C (1985) Chronic pilonidal disease: a randomized trial with a complete 3-year follow-up. Br J Surg 72:303–304
- Chaudhuri A, Bekdash BA, Taylor AL (2006) Single-dose metronidazole vs 5-day multi-drug antibiotic regimen in excision of pilonidal sinuses with primary closure: a prospective, randomized, double-blinded pilot study. Int J Colorectal Dis 21:688–692

- Lundhus E, Gjøde P, Gottrup F, Holm CN, Terpling S (1989) Bactericidal antimicrobial cover in primary suture of perianal or pilonidal abscess. A prospective, randomized, double-blind clinical trial. Acta Chir Scand 155:351–354
- Ruszczak Z, Friess W (2003) Collagen as a carrier for on-site delivery of antibacterial drugs. Adv Drug Deliv Rev 55:1679–1698
- 13. Musella M, Guido A, Musella S (2001) Collagen tampons as aminoglycoside carriers to reduce postoperative infection rate in prosthetic repair of groin hernias. Eur J Surg 167:130–132
- 14. Andersson RE, Lukas G, Skullman S, Hugander A (2010) Local administration of antibiotics by gentamicin-collagen sponge does not improve wound healing or reduce recurrence rate after pilonidal excision with primary suture: a prospective randomized controlled trial. World J Surg 34:3042–3048
- Vogel P, Lenz J (1992) Treatment of pilonidal sinus with excision and primary suture using a local, resorbable antibiotic carrier. Results of a prospective randomized study. Chirurg 63:748–753
- Yetim I, Ozkan OV, Dervişoglu A, Erzurumlu K, Canbolant E (2010) Effect of gentamicin-absorbed collagen in wound healing in pilonidal sinus surgery: a prospective randomized study. J Int Med Res 38:1029–1033
- Holzer B, Grüssner U, Brückner B, EMD study group et al (2003) Efficacy and tolerance of a new gentamicin collagen fleece (Septocoll) after surgical treatment of a pilonidal sinus. Colorectal Dis 5:222–227
- Rao MM, Zawislak W, Kennedy R, Gilliland R (2010) A prospective randomised study comparing two treatment modalities for chronic pilonidal sinus with a 5-year follow-up. Int J Colorectal Dis 25:395–400
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group (2010) Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Int J Surg 8:336–341
- Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The cochrane collaboration. http://www.cochrane-handbook.org. Accessed 22 Feb 2014
- Centre for evidence based-medicine at University of Oxford (2011) The Oxford 2011 Levels of evidence. http://www.cebm. net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1. pdf. Accessed 22 Feb 2014
- 22. Doll D, Evers T, Matevossian E, Hoffmann S, Krapohl B, Bartsch D (2011) Does gentamycin affect long term recurrence rate in pilonidal sinus surgery? Eur Surg 43:236–243
- 23. Chang WK, Srinivasa S, MacCormick AD, Hill AG (2013) Gentamicin-collagen implants to reduce surgical site infection: systematic review and meta-analysis of randomized trials. Ann Surg 258:59–65
- Friberg O, Dahlin LG, Levin LA et al (2002) Cost effectiveness of local collagen-gentamicin as prophylaxis for sternal wound infections in different risk groups. Scand Cardiovasc J 40:117–125